Diffuse intrinsic pontine gliomas: A systematic update on clinical trials and biology

M. H.A. Jansen; D. G. van Vuurden; W. P. Vandertop; G. J.L. Kaspers

doi:10.1016/j.ctrv.2011.06.007

Diffuse intrinsic pontine gliomas: A systematic update on clinical trials and biology

M. H.A. Jansen^*, D. G. van Vuurden, W. P. Vandertop, G. J.L. Kaspers

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

96 Citations (Scopus)

Abstract

Patients with diffuse intrinsic pontine gliomas (DIPG) have a poor prognosis. Although DIPG constitute only 10-15% of all pediatric brain tumors, they are the main cause of death in this group. Despite 26 clinical trials in newly diagnosed DIPG in the past 5. years (including several targeted agents), there is no clear improvement in prognosis. However, knowledge on DIPG biology is increasing, mainly due to the (re)introduction of biopsies and autopsies, the possibility of gene expression profiling, and the development of in vivo models. Translation of this knowledge into clinical trials in combination with improved drug distribution methods may eventually lead to more effective treatment of this devastating disease.

Original language	English
Pages (from-to)	27-35
Number of pages	9
Journal	Cancer Treatment Reviews
Volume	38
Issue number	1
DOIs	https://doi.org/10.1016/j.ctrv.2011.06.007
Publication status	Published - 1 Feb 2012

Keywords

Brain stem
Glioma
Molecular targeted therapy
Pontine glioma
Pontine tumors

Access to Document

10.1016/j.ctrv.2011.06.007

Cite this

@article{97399ea949c64d42a53b41857f87f280,

title = "Diffuse intrinsic pontine gliomas: A systematic update on clinical trials and biology",

abstract = "Patients with diffuse intrinsic pontine gliomas (DIPG) have a poor prognosis. Although DIPG constitute only 10-15% of all pediatric brain tumors, they are the main cause of death in this group. Despite 26 clinical trials in newly diagnosed DIPG in the past 5. years (including several targeted agents), there is no clear improvement in prognosis. However, knowledge on DIPG biology is increasing, mainly due to the (re)introduction of biopsies and autopsies, the possibility of gene expression profiling, and the development of in vivo models. Translation of this knowledge into clinical trials in combination with improved drug distribution methods may eventually lead to more effective treatment of this devastating disease.",

keywords = "Brain stem, Glioma, Molecular targeted therapy, Pontine glioma, Pontine tumors",

author = "Jansen, {M. H.A.} and {van Vuurden}, {D. G.} and Vandertop, {W. P.} and Kaspers, {G. J.L.}",

year = "2012",

month = feb,

day = "1",

doi = "10.1016/j.ctrv.2011.06.007",

language = "English",

volume = "38",

pages = "27--35",

journal = "Cancer Treatment Reviews",

issn = "0305-7372",

publisher = "W.B. Saunders Ltd",

number = "1",

}

TY - JOUR

T1 - Diffuse intrinsic pontine gliomas

T2 - A systematic update on clinical trials and biology

AU - Jansen, M. H.A.

AU - van Vuurden, D. G.

AU - Vandertop, W. P.

AU - Kaspers, G. J.L.

PY - 2012/2/1

Y1 - 2012/2/1

N2 - Patients with diffuse intrinsic pontine gliomas (DIPG) have a poor prognosis. Although DIPG constitute only 10-15% of all pediatric brain tumors, they are the main cause of death in this group. Despite 26 clinical trials in newly diagnosed DIPG in the past 5. years (including several targeted agents), there is no clear improvement in prognosis. However, knowledge on DIPG biology is increasing, mainly due to the (re)introduction of biopsies and autopsies, the possibility of gene expression profiling, and the development of in vivo models. Translation of this knowledge into clinical trials in combination with improved drug distribution methods may eventually lead to more effective treatment of this devastating disease.

AB - Patients with diffuse intrinsic pontine gliomas (DIPG) have a poor prognosis. Although DIPG constitute only 10-15% of all pediatric brain tumors, they are the main cause of death in this group. Despite 26 clinical trials in newly diagnosed DIPG in the past 5. years (including several targeted agents), there is no clear improvement in prognosis. However, knowledge on DIPG biology is increasing, mainly due to the (re)introduction of biopsies and autopsies, the possibility of gene expression profiling, and the development of in vivo models. Translation of this knowledge into clinical trials in combination with improved drug distribution methods may eventually lead to more effective treatment of this devastating disease.

KW - Brain stem

KW - Glioma

KW - Molecular targeted therapy

KW - Pontine glioma

KW - Pontine tumors

UR - http://www.scopus.com/inward/record.url?scp=84855913314&partnerID=8YFLogxK

U2 - 10.1016/j.ctrv.2011.06.007

DO - 10.1016/j.ctrv.2011.06.007

M3 - Review article

C2 - 21764221

AN - SCOPUS:84855913314

SN - 0305-7372

VL - 38

SP - 27

EP - 35

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

IS - 1

ER -

Diffuse intrinsic pontine gliomas: A systematic update on clinical trials and biology

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this